The professor of neurology at both the University of California San Francisco and King’s College, London, spoke about the results from a phase 2b/3 study evaluating atogepant for prevention of migraine.
Peter Goadbsy, MD, PhD, DSc
Advertisement
Articles by Peter Goadbsy, MD, PhD, DSc
Goadsby spoke about differentiating between the foursome of preventive therapies soon to be available to physicians.
Advertisement
Latest Updated Articles
Peter Goadbsy, MD, PhD, DSc: Differentiating Between CGRPs, Synthesizing the GepantsPublished: September 2nd 2018 | Updated:
Peter Goadbsy, MD, PhD, DSc: Atogepant Has Potential as Migraine ProphylacticPublished: June 20th 2019 | Updated:
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Issues Complete Response Letter for Spinocerebellar Ataxia Agent Troriluzole
2
New Phase 3 Study to Evaluate Remibrutinib in Generalized Myasthenia Gravis Treatment
3
FDA Approves Doxecitine and Doxribtimine Combination Therapy as First Treatment for Thymidine Kinase 2 Deficiency
4
Surveying Global Nursing Needs for Patients With Generalized Myasthenia Gravis: Amy Perrin Ross, APN, MSN, CNRN, MSCN
5
